Lucky Core Industries Limited (PSX: LCI) has completed the purchase of a manufacturing facility owned by Pfizer Pakistan Limited located at B2 SITE Karachi, along with the acquisition of certain pharmaceutical products, LCI informed the main bourse on Monday.
The asset acquisition was completed on September 06, 2024 in accordance with the Asset Purchase Agreements entered into between the parties, the stock filing revealed.
Product registrations consist of: (1) Ansaid, (2) Ponstan, (3) Ponstan Forte, (4) Basoquin, (5) Deltacortril, (6) Lysovit, (7) Corex-D, and (8) Mycitracin, and trademarks associated with the said pharmaceutical products from relevant Pfizer group entities.
At the time of filing, LCI’s scrip at the bourse was Rs. 1,019.99, up 0.49 percent or Rs. 5 with a turnover of 22,708 shares on Monday.
Get the latest business news, market insights, and economic updates wherever you prefer.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.